scholarly journals An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy

Molecules ◽  
2021 ◽  
Vol 26 (19) ◽  
pp. 5847
Author(s):  
Juliana T. W. Tong ◽  
Paul W. R. Harris ◽  
Margaret A. Brimble ◽  
Iman Kavianinia
Keyword(s):  
Cancer Therapy ◽  
Therapeutic Approach ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Fda Approval ◽  
Significant Interest ◽  
Suitable Combination ◽  
Insight Into ◽  
Antibody Drug

The large number of emerging antibody-drug conjugates (ADCs) for cancer therapy has resulted in a significant market ‘boom’, garnering worldwide attention. Despite ADCs presenting huge challenges to researchers, particularly regarding the identification of a suitable combination of antibody, linker, and payload, as of September 2021, 11 ADCs have been granted FDA approval, with eight of these approved since 2017 alone. Optimism for this therapeutic approach is clear, despite the COVID-19 pandemic, 2020 was a landmark year for deals and partnerships in the ADC arena, suggesting that there remains significant interest from Big Pharma. Herein we review the enthusiasm for ADCs by focusing on the features of those approved by the FDA, and offer some thoughts as to where the field is headed.

scholarly journals Antibody–Drug Conjugates for Cancer Therapy

Molecules ◽  
2020 ◽  
Vol 25 (20) ◽  
pp. 4764
Author(s):  
Umbreen Hafeez ◽  
Sagun Parakh ◽  
Hui K. Gan ◽  
Andrew M. Scott
Keyword(s):  
Monoclonal Antibody ◽  
Molecular Imaging ◽  
Cancer Therapy ◽  
Normal Tissue ◽  
Clinical Development ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Novel Drugs ◽  
Antibody Drug

Antibody–drug conjugates (ADCs) are novel drugs that exploit the specificity of a monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the delivery of a potent cytotoxic payload. ADCs provide a unique opportunity to deliver drugs to tumor cells while minimizing toxicity to normal tissue, achieving wider therapeutic windows and enhanced pharmacokinetic/pharmacodynamic properties. To date, nine ADCs have been approved by the FDA and more than 80 ADCs are under clinical development worldwide. In this paper, we provide an overview of the biology and chemistry of each component of ADC design. We briefly discuss the clinical experience with approved ADCs and the various pathways involved in ADC resistance. We conclude with perspectives about the future development of the next generations of ADCs, including the role of molecular imaging in drug development.

scholarly journals Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy

Molecules ◽  
2017 ◽  
Vol 22 (8) ◽  
pp. 1281 ◽  
Author(s):  
Hao Chen ◽  
Zongtao Lin ◽  
Kinsie Arnst ◽  
Duane Miller ◽  
Wei Li
Keyword(s):  
Cancer Therapy ◽  
Tubulin Inhibitor ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Antibody Drug

scholarly journals Antibody–Drug Conjugates for Cancer Therapy

Biomedicines ◽  
2016 ◽  
Vol 4 (3) ◽  
pp. 14 ◽  
Author(s):  
Adam Parslow ◽  
Sagun Parakh ◽  
Fook-Thean Lee ◽  
Hui Gan ◽  
Andrew Scott
Keyword(s):  
Cancer Therapy ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Antibody Drug

scholarly journals Antibody–drug conjugates and other nanomedicines: the frontier of gynaecological cancer treatment

2016 ◽  
Vol 6 (6) ◽  
pp. 20160054 ◽  
Author(s):  
David Howard ◽  
Jetzabel Garcia-Parra ◽  
Gareth D. Healey ◽  
Cynthia Amakiri ◽  
Lavinia Margarit ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Clinical Trials ◽  
Cancer Therapy ◽  
Rational Design ◽  
State Of The Art ◽  
Cervix Uterus ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Liposomal Drugs ◽  
Antibody Drug

Gynaecological cancers: malignancies of the cervix, uterus, ovaries, vagina and vulva, are responsible for over 1.1 million new cancer cases and almost half a million deaths annually. Ovarian cancer in particular is difficult to treat due to often being diagnosed at a late stage, and the incidence of uterine and vulvar malignancies are both on the rise. The field of nanomedicine is beginning to introduce drugs into the clinic for oncological applications exemplified by the liposomal drugs, Doxil and Myocet, the nanoparticle, Abraxane and antibody–drug conjugates (ADCs), Kadcyla and Adcetris. With many more agents currently undergoing clinical trials, the field of nanomedicine promises to have a significant impact on cancer therapy. This review considers the state of the art for nanomedicines currently on the market and those being clinically evaluated for the treatment of gynaecological cancers. In particular, it focuses on ADCs and presents a methodology for their rational design and evaluation.

Sign in / Sign up

Export Citation Format

Share Document